Background
==========

Polymyositis (PM) and dermatomyositis (DM) are idiopathic inflammatory myopathies (IIM), a group of autoimmune disorders characterized by inflammation present predominantly in muscle tissues. The chief clinical presentations include symmetric proximal muscle weakness, other organ involvement, and presence of autoantibodies \[[@B1]\]. Although the underlying pathogenesis for PM and DM remains unclear, evidence has suggested that, like many other autoimmune conditions, these disorders likely result from a combination of environmental exposure and genetic susceptibility \[[@B2]\]. Genetic variability in the human leukocyte antigen (*HLA*) genes is thought to play an important role in DM and PM pathogenesis \[[@B3],[@B4]\]. This may be partly attributed to the influence of HLA molecules on T-cell receptor development, peripheral tolerance, and immune response to environmental agents. It has been established that geographic locations and ethnicities may affect susceptibility to autoimmune diseases \[[@B5],[@B6]\]. The *HLA-DRB1\*0301* and *HLA-DQA1\*0501* alleles have been reported as risk factors for myositis in Western populations \[[@B7],[@B8]\], whereas *DRB1\*0803* may increase PM susceptibility among the Japanese population \[[@B9]\]. In studies of 52 DM and PM patients from Northern China, Han *et al.* reported positive associations between the *HLA-DRB1\*04*, *HLA-DRB1\*07*, and *HLA-DRB1\*12* alleles and DM development \[[@B10]\]. They also observed that *HLA-DQB1\*0401* is a risk factor for DM and PM \[[@B11]\]. However, the sample sizes of these studies were small; therefore, the possible role of *HLA* class II alleles in myopathies in Chinese patients requires further investigation.

To assess the effect of polymorphisms in *HLA-DRB1*, *HLA*-*DQA1*, and *HLA*-*DQB1* on DM and PM susceptibility, we conducted a study of 91 adult patients with DM or PM and 113 healthy controls in a Han Chinese population. Our results demonstrate that *HLA* class II alleles may influence adult DM and PM susceptibility in the Han Chinese population.

Methods
=======

Study subjects
--------------

Between August 2009 and March 2012, 71 and 20 patients were diagnosed with DM and PM, respectively, at the Huashan Hospital of Fudan University in Shanghai, China. The patients met probable or definite diagnosis of DM or PM according to the Bohan and Peter \[[@B12]\] criteria \[[@B12],[@B13]\]. Lung lesions were examined by chest computed tomography, and a diagnosis of interstitial lung disease (ILD) or idiopathic interstitial pneumonitis was made by a pulmonologist. All patients were ethnic Han Chinese (25 males and 66 females, median age of 51 ± 15.8 years). One hundred and thirteen healthy Han Chinese subjects (36 males and 77 females, median age of 40.0 ± 8.6 years) with no history of autoimmune disease were enrolled in the study as controls. The study followed protocols set by the Declaration of Helsinki and was approved by the ethics committee of Huashan Hospital. All patients and controls provided written informed consent prior to the study.

Experiments
-----------

DNA was extracted from blood using the Qiagen DNA extraction kit (Qiagen; Hilden, Germany). Low- and high-resolution typing of the *HLA-DRB1*, *HLA*-*DQA1*, and *HLA*-*DQB1* alleles were performed using the polymerase chain reaction (PCR)-sequence-specific primed (SSP) procedure described by Olerup *et al*. \[[@B14],[@B15]\]. Serum was obtained from all patients for detection of myositis-specific antibodies (MSA; anti-Jo-1 autoantibodies) and myositis-associated antibodies (MAA; anti-Ro and anti-La autoantibodies). Autoantibodies were analyzed by an indirect immunofluorescence method using the kits from EUROIMMUN AG (Lubeck, Germany).

Statistical analysis
--------------------

The allele, genotype, and haplotype frequencies of the *HLA* loci were compared between the patients and controls using the Fisher exact test or chi-square test, as appropriate. Data were expressed as odds ratios (ORs) with 95% confidence intervals (CIs). A *p-*value ≤ 0.05 was considered statistically significant. In multiple comparisons, *p-*values were adjusted using the Bonferroni correction to give a corrected *p-*value (*p*~corr~). A *p*-value ≤ 0.05 before correction for multiple comparisons was considered as possibly statistically significant. The Hardy--Weinberg equilibrium constant in the control group was confirmed using a chi-square test. Putative haplotypes were inferred from unphased genotype data using the Bayesian statistical method available in the PHASE program v2.1.1 \[[@B16]\]. Putative haplotypes with a frequency higher than 3% among the controls were selected for further comparisons between the patients and controls. Unless otherwise stated, Stata (version 7.0; Stata Corp.; College Station, TX, USA) statistical software was used to perform the statistical analyses.

Results
=======

Of the 91 patients, 71 had been diagnosed with DM and 20 with PM (66 female and 25 male \[2.64:1\]). Although most of the patients were positive for antinuclear antibodies, few were positive for either MSA or MAA. The frequencies of MSA and MAA were higher in the PM group than in the DM group (10% vs. 1.4%, *p* = 0.06 for MSA; 20% vs. 5.63%, *p* = 0.05 for MAA). As expected, cutaneous involvement such as rash or cuticular overgrowth was present only in DM patients. Approximately half of the patients had ILD, with a higher prevalence among patients with PM than those with DM (76.5% vs. 37.7%, *p* = 0.04). No significant differences in other clinical features were observed between the two groups (Table [1](#T1){ref-type="table"}).

###### 

Clinical features of patients with DM and PM

                                 **DM n (%) (N = 71)**   **PM n (%) (N = 20)**   ***p*(DM vs. PM)**
  ----------------------------- ----------------------- ----------------------- --------------------
  Serologic group                                                                         
   MSA (anti-Jo-1)                      1 (1.4)                 2 (10)                  0.06
   MAA (SSA, SSB or Scl)               4 (5.63)                 4 (20)                  0.05
  Clinical presentations                                                                  
   Fever                                4 (5.6)                  1 (5)                  0.92
   Raynaud's disease                     0.00                    1 (5)                  0.06
   Arthritis                            1 (1.4)                  0.00                   0.59
   Interstitial lung disease         26^1^ (37.7)            13^2^ (76.5)               0.04
   Palpitations                         1 (1.4)                  0.00                   0.59
   Dysphagia                           10 (14.1)                4 (20)                  0.51
   V-sign                              26 (36.6)                 0.00                   n/a
   Gottron papules                     24 (33.8)                 0.00                   n/a
   Periorbital edematous rash          11 (15.5)                 0.00                   n/a
   Shawl sign                          13 (18.3)                 0.00                   n/a
   Cuticular overgrowth                 3 (4.2)                  0.00                   n/a

MSA: myositosis-specific autoantiboides; MAA: myositosis associated autoantibodies;

^1^69 DM patients evaluated; ^2^17 PM patients evaluated; n/a: not applicable.

Genotyping analyses of the *HLA-DQA1* and *HLA-DQB1* loci were performed to study the relationship between the *HLA* class II alleles and susceptibility to DM and PM. Because there are several lines of evidence to suggest that DM and PM may be distinct diseases with different genetic backgrounds \[[@B17]\], we analyzed the influence of the *HLA* alleles on susceptibility to DM and PM individually rather than analyzing the combined DM/PM group (Table [2](#T2){ref-type="table"}). Compared with the controls, the frequency of *HLA-DQA1*\**0104* was significantly higher in the DM group than in the PM group (16.42% vs. 8.18%, *p* = 0.01, *p*~*corr*~ NS; OR = 2.58; 95% CI: 1.18--5.74), implying a possible positive correlation between *HLA-DQA1*\**0104* and the risk of DM. Of the *HLA-DQB1* alleles analyzed, only the *HLA-DQB1*\**0303* frequency was lower in patients with ILD than in the controls (6.76% vs. 19.03%, *p* = 0.01, *p*~*corr*~ NS; OR = 0.25; 95% CI: 0.07 − 0.73), implying that patients with this allele are less likely to develop the lung complication. This was further confirmed by the fact that the *HLA-DQB1*\**0303* frequency was lower among those who developed ILD (*p* \< 0.01; OR = 0.19; 95% CI: 0.038--0.37) than those who did not develop ILD. *HLA-DRB1* typing analysis showed that compared to controls, DM patients had a considerably lower prevalence of *HLA-DRB1*\**03* (3.08% vs. 11.27%, *p* = 0.01, *p*~*corr*~ NS; OR = 0.26; 95% CI: 0.06--0.81) and a higher frequency of *HLA-DRB1*\**07* (20.77% vs. 13.24%, *p* = 0.01, *p*~*corr*~ NS, OR = 2.26, 95% CI, 1.12--4.59). Both *HLA-DRB1\*04* and *HLA-DRB1\*12* alleles are likely linked to the lung disease (*p* = 0.01, *p*~*corr*~ NS; OR = 2.82; 95% CI: 1.15--6.76 and *p* = 0.02, *p*~*corr*~ NS; OR = 2.52; 95% CI: 1.02--6.07, respectively). A similar effect of *HLA-DRB1\*04* on ILD development was also observed when the allele frequencies between patients with and without the lung complication were compared (*p* = 0.026; OR = 3.32; 95% CI: 1.22--9.08). Comparison of *HLA-DRB1\*12* allele frequencies between myositis patients with and without ILD showed a similar trend of being higher among those with ILD than among those without, although the difference between the two groups was not statistically significant (*p* = 0.35; OR = 1.59; 95% CI: 0.63--4.00). This is likely attributable to the small numbers in the groups examined. Moreover, the *HLA-DRB1\*07* allele showed a possible influence on the development of esophageal/muscle complications (30.00% vs. 13.24%, *p* = 0.01, *p*~*corr*~ NS; OR = 4.78; 95% CI: 1.03--24.42). A similar trend for a higher *HLA-DRB1\*07* allele frequency was also noted among patients who had dysphagia as compared to those who did not (*p* = 0.057; OR = 3.55; 95% CI: 0.91--13.82).

###### 

***HLA-DQA1*,*HLA-DQB1,*and*HLA-DRB1*allele frequencies in PM and DM patients and controls**

   **Loci/alleles**      **DM**         **PM**     **Myositis with ILD**   **Myositis with dysphagia**   **Control**   **Control vs. indicated patients (*p*; OR (95% CI))**                        
  ------------------ --------------- ------------ ----------------------- ----------------------------- ------------- ------------------------------------------------------- ----- --------------- ---------------
      *HLA-DRB1*         N = 65         N = 19            N = 37                     N = 10                N = 113                                                                                          
         \*01           1 (0.77)       0 (0.00)          1 (1.35)                   0 (0.00)              5 (2.45)                              n/s                            n/a        n/s             n/a
         \*03           4 (3.08)      4 (10.53)          4 (5.41)                   1 (5.00)             23 (11.27)                        0.01^1^; 0.26                       n/s        n/s             n/s
     (0.06--0.81)                                                                                                                                                                                   
         \*04          17 (13.08)     6 (15.79)         15 (20.27)                  2 (10.00)            22 (10.78)                             n/s                            n/s   0.01^1^; 2.82        n/s
     (1.15--6.76)                                                                                                                                                                                   
         \*07          27 (20.77)      1 (2.63)         14 (18.92)                  6 (30.00)            27 (13.24)                        0.01^1^; 2.26                       n/s        n/s        0.01^1^; 4.78
     (1.12--4.59)     (1.03--24.42)                                                                                                                                                                 
         \*08          13 (10.00)     4 (10.53)          7 (9.46)                   2 (10.00)             17 (8.33)                             n/s                            n/s        n/s             n/s
         \*09          20 (15.38)      2 (5.26)          3 (4.05)                   3 (15.00)            26 (12.75)                             n/s                            n/s        n/s             n/s
         \*10           2 (1.54)       1 (2.63)          2 (2.70)                   0 (0.00)              3 (1.47)                              n/s                            n/s        n/s             n/a
         \*11           3 (2.31)       3 (7.89)          2 (2.70)                   0 (0.00)              9 (4.41)                              n/s                            n/s        n/s             n/a
         \*12          20 (15.38)     7 (18.42)         14 (18.92)                  1 (5.00)             22 (10.78)                             n/s                            n/s   0.02^1^; 2.52        n/s
     (1.02--6.07)                                                                                                                                                                                   
         \*13           7 (5.38)       1 (2.63)          2 (2.70)                   1 (5.00)              8 (3.92)                              n/s                            n/s        n/s             n/s
         \*14           2 (1.54)       3 (7.89)          1 (1.35)                   2 (10.00)             9 (4.41)                              n/s                            n/s        n/s             n/s
         \*15           10 (7.69)     4 (10.53)          7 (9.46)                   1 (5.00)             29 (14.22)                             n/s                            n/s        n/s             n/s
         \*16           4 (3.08)       2 (5.26)          2 (2.70)                   1 (5.00)              4 (1.96)                              n/s                            n/s        n/s             n/s
      *HLA-DQA1*         N = 67         N = 20            N = 39                     N = 12                N = 110                                                                                          
        \*0101          9 (6.72)       0 (0.00)          5 (6.41)                   1 (4.17)              11 (5.00)                             n/s                            n/a        n/s             n/s
        \*0102         18 (13.43)     10 (25.00)        16 (20.51)                  4 (16.67)            44 (20.00)                             n/s                            n/s        n/s             n/s
        \*0103         26 (19.40)     6 (15.00)         10 (12.82)                  6 (25.00)            28 (12.73)                             n/s                            n/s        n/s             n/s
        \*0104         22 (16.42)     4 (10.00)         11 (14.10)                  4 (16.67)             18 (8.18)                        0.01^1^; 2.58                       n/s        n/s             n/s
     1.18--5.64)                                                                                                                                                                                    
        \*0201          1 (0.75)       2 (5.00)          1 (1.28)                   0 (0.00)              1 (0.45)                              n/s                            n/s        n/s             n/a
        \*0301         44 (32.84)     9 (22.50)         26 (33.33)                  9 (37.50)            85 (38.64)                             n/s                            n/s        n/s             n/s
        \*0302          1 (0.75)       0 (0.00)          0 (0.00)                   0 (0.00)              1 (0.45)                              n/s                            n/a        n/a             n/a
        \*0401          1 (0.75)       2 (5.00)          2 (2.56)                   0 (0.00)              3 (1.36)                              n/s                            n/s        n/s             n/a
        \*0501          11 (8.21)     6 (15.00)          6 (7.69)                   0 (0.00)             28 (12.73)                             n/s                            n/s        n/s             n/a
        \*0507          1 (0.75)       0 (0.00)          0 (0.00)                   0 (0.00)              0 (0.00)                              n/a                            n/a        n/a             n/a
        \*0601          0 (0.00)       1 (2.50)          1 (1.28)                   0 (0.00)              1 (0.45)                              n/a                            n/s                          
      *HLA-DQB1*         N = 67         N = 17            N = 37                     N = 10                N = 113                                                                                          
        \*0201         31 (23.48)     6 (16.67)         16 (21.62)                  5 (25.00)            44 (19.47)                             n/s                            n/s        n/s             n/s
        \*0301         20 (15.15)     9 (25.00)         15 (20.27)                  0 (0.00)             35 (15.49)                            n./s                            n/s        n/s             n/a
        \*0302          9 (6.82)       2 (5.56)          7 (9.46)                   1 (5.00)              12 (5.31)                             n/s                            n/s        n/s             n/s
        \*0303         24 (18.18)      2 (5.56)          5 (6.76)                   5 (25.00)            43 (19.03)                             n/s                            n/s   0.01^1^; 0.25        n/s
     (0.07--0.73)                                                                                                                                                                                   
        \*0401          6 (4.55)       2 (5.56)          6 (8.11)                   1 (5.00)              7 (3.10)                              n/s                            n/s        n/s             n/s
        \*0402          0 (0.00)       1 (2.78)          1 (1.35)                   0 (0.00)              1 (0.44)                             n.a.                            n/s        n/s             n/a
        \*0501          1 (0.76)       2 (5.56)          3 (4.05)                   0 (0.00)              8 (3.54)                              n/s                            n/s        n/s             n/a
        \*0502          5 (3.79)       2 (5.56)          5 (6.76)                   0 (0.00)              7 (3.10)                              n/s                            n/s        n/s             n/a
        \*0503           4(3.03)       1 (2.78)          0 (0.00)                   2 (10.00)             8 (3.54)                              n/s                            n/s        n/a             n/s
        \*0601         20 (15.15)     7 (19.44)         11 (14.86)                  3 (15.00)            33 (14.60)                             n/s                            n/s        n/s             n/s
        \*0602          4 (3.03)       2 (5.56)          2 (2.70)                   2 (10.00)             16 (7.08)                             n/s                            n/s        n/s             n/s
        \*0604          5 (3.79)       0 (0.00)          2 (2.70)                   0 (0.00)              5 (2.21)                              n/s                            n/a        n/s             n/a
        \*0608          3 (2.27)       0 (0.00)          1 (1.35)                   1 (5.00)              7 (3.10)                              n/s                            n/a        n/s             n/s

n/s: not significant; n/a: not applicable; ^1^*p*corr greater than 0.05; ILD: interstitial lung disease.

We then examined the association between putative haplotypes involving the *DRB1-DQA1-DQB1* loci and susceptibility to DM, PM, lung, and esophageal complications. In this analysis, only the putative haplotypes present in at least 3% of the controls were selected for further study. Of the 12 putative haplotypes selected, the frequency of *DRB1\*07-DQA1\*01-DQB1\*02* was higher in the DM group (*p* = 0.03, *p*~*corr*~ NS; OR = 2.90; 95% CI: 1.02--8.93) and in patients with ILD (*p* = 0.02, *p*~*corr*~ NS; OR = 3.45; 95% CI: 1.04--11.58) than in the controls, indicating that this putative haplotype might increase the risk of DM and the lung complication (Table [3](#T3){ref-type="table"}). A further comparison of the *DRB1\*07-DQA1\*01-DQB1\*02* frequency in patients who developed dysphagia with those who did not showed a trend for a higher frequency of this haplotype among patients with dysphagia, although the difference between the groups was not statistically significant (*p* = 0.23; OR = 2.27; 95% CI: 0.68--7.72). Again, we consider that this result is likely due to the small sample sizes in both groups.

###### 

**Comparisons of frequencies of*HLA*class II putative haplotypes between DM and PM and controls**

   **Haplotypes**   **DM (N =63)**   **PM (N = 18)**   **Myositis with ILD**   **Myositis with dysphagia**   **Control (N =100)**   **Controls vs. indicated patients (*p*; OR \[95% CI\])**                        
  ---------------- ---------------- ----------------- ----------------------- ----------------------------- ---------------------- ---------------------------------------------------------- ----- --------------- -----
      03-05-02         2 (1.59)         2 (5.56)             2 (2.78)                   0 (0.00)                  11 (5.50)                                   n/s                              n/s        n/s        n/s
      04-03-03         6 (4.36)         1 (2.78)             5 (6.94)                   1 (5.56)                   9 (4.50)                                   n/s                              n/s        n/s        n/s
      04-03-04         5 (3.97)         2 (5.56)             5 (6.94)                   1 (5.56)                   6 (3.00)                                   n/s                              n/s        n/s        n/s
      07-01-02        12 (9.52)         1 (2.78)             8 (11.11)                  2 (11.11)                  7 (3.50)                              0.03^1^; 2.90                         n/s   0.02^1^; 3.45   n/s
    (1.02--8.93)    (1.04--11.58)                                                                                                                                                                                   
      07-03-02         6 (4.76)         0 (0.00)             3 (4.17)                   2 (11.11)                 11 (5.50)                                   n/s                              n/s        n/s        n/s
      08-01-06        13 (10.32)        3 (8.33)             6 (8.33)                   2 (11.11)                 13 (6.50)                                   n/s                              n/s        n/s        n/s
      09-03-03        17 (13.49)        2 (5.56)             3 (4.17)                   3 (16.67)                 20 (10.00)                                  n/s                              n/s        n/s        n/s
      11-05-03         3 (2.38)         1 (2.78)             1 (1.39)                   0 (0.00)                   7 (3.50)                                   n/s                              n/s        n/s        n/s
      12-01-03        11 (8.73)         2 (5.56)             8 (11.11)                  0 (0.00)                  11 (5.50)                                   n/s                              n/s        n/s        n/s
      13-01-06         7 (5.56)         0 (0.00)             2 (2.78)                   1 (5.56)                   7 (3.50)                                   n/s                              n/s        n/s        n/s
      14-01-05         2 (1.59)         1 (2.78)             0 (0.00)                   2 (11.11)                  7 (3.50)                                   n/s                              n/s        n/s        n/s
      15-01-06         7 (5.56)         3 (8.33)             3 (4.17)                   1 (5.56)                  19 (9.50)                                   n/s                              n/s        n/s        n/s

n/s: not significant; n/a: not applicable; ^1^*p*corr greater than 0.05; ILD: interstitial lung disease.

Discussion
==========

There are differences in the clinical features of DM and PM between our cohort of Han Chinese patients and Western patients \[[@B1],[@B18]\]. There are more DM cases in our cohort and among Mesoamerican patients, whereas PM is the major subtype among Caucasian patients \[[@B19]\]. Compared to Caucasian patients, our cohort had a higher prevalence of the lung complication \[[@B20]\]. The frequencies of dysphagia were comparable between our cohort and those reported in the West \[[@B1],[@B21]\]. Approximately 30--40% of Caucasian and African American IIM patients are positive for MSA/MAA autoantibodies \[[@B19],[@B22]\]. Although the proportion of patients who were positive for autoantibodies was relatively low in our cohort, it is nonetheless comparable to findings from other studies in Chinese patients \[[@B23],[@B24]\].

There is a growing body of evidence to suggest that differences in the impact of *HLA* class II alleles on the susceptibility to DM and PM may exist among different ethnic groups and geographic locations \[[@B19],[@B20],[@B25]-[@B27]\]. It has been well documented that *HLA* class II alleles that form the 8.1 ancestral haplotype (8.1 AH), *DRB1\*03-DQA1\*05-DQB1\*02*, are closely linked to DM and PM in Western populations \[[@B4],[@B7],[@B28]\]. Previous studies suggest that *HLA-DQA1\*0501* and *HLA-DRB1\*0301* may be risk factors for PM, whereas *HLA-DQA1\*0201* and *HLA-DRB1\*0401* confer protection against the disease in Caucasians \[[@B4],[@B28]-[@B30]\]. Moreover, *HLA-DRB1\*07* has been reported to protect against PM and IIM in Caucasians and African Americans \[[@B4],[@B22],[@B28]\]. In their study of African American patients with IIM, O'Hanlon *et al.*\[[@B22]\] demonstrated that *HLA-DRB1\*14* and *HLA-DRB1\*0301* increase the risk of DM, while *HLA-DRB1\*0301* influences PM susceptibility. Furuya *et al.*\[[@B9],[@B26]\] found that both *HLA-DRB1\*0803* and *HLA-DQA1\*0501* provide an increased risk of DM but a reduced risk of PM in a Japanese population. In a study of 25 Korean patients with IIM, Rider *et al*. \[[@B27]\] reported that *HLA-DRB1\*14* as a protective factor for DM and PM. To date, most studies on the subject have been focused on Western populations. In their studies of 52 DM and PM patients from Northern China, Han *et al.* reported that *HLA-DRB1\*04*, *HLA-DRB1\*07*, and *HLA-DRB1\*12* may render an increased risk of DM \[[@B10]\], while *HLA-DQB1\*0401* may have an impact on IIM susceptibility \[[@B11]\]. Our data demonstrate that the *HLA-DQA1\*0104* and *HLA-DRB1\*07* alleles are likely associated with an increased risk of DM, whereas *HLA-DRB1\*03* may provide protection against DM. Although 8.1 AH is known as a risk factor for IIM among individuals of Northwestern European descent \[[@B4],[@B7],[@B28]\], such an association has not been established in other ethnic groups \[[@B25]\]. *DRB1\*03*-*DQA1\*05*-*DQB1\*02* is not a major haplotype in our cohort and does not influence DM and PM susceptibility. Our results suggest that the *HLA-DRB1\*07-DQA1\*01-DQB1\*02* haplotype may be associated with DM and ILD.

It is interesting to note that *HLA-DRB1\*07* influences IIM susceptibility among various ethnic groups. In our study of Han Chinese patients, the *HLA-DRB1\*07* allele in the putative haplotype *DRB1\*07*-*DQA1\*01*-*DQB1\*02* was found to be a risk factor for DM, but the same allele present in the *DRB1\*07*-*DQA1\*02*-*DQB1\*02* haplotype was reported to be a protector against IIM in Caucasians and African Americans \[[@B4],[@B22],[@B25],[@B28]\]. These findings imply that *HLA-DRB1\*07* might have opposite effects on the diseases in different ethnic groups. Similar phenomena have been observed for the effect of *HLA-DQA1\*0501* on IIM. This allele was reported as a protective factor against IIM in a Japanese population \[[@B9]\] but as a risk factor for IIM among US Caucasians \[[@B29]\]. Although it is unclear what might cause such different effects, possible explanations include referral bias, small sample sizes resulting in nonrepresentative populations, different pathogeneses, various environmental risk triggers around the world, and unidentified genetic loci responsible for disease development.

Furuya *et al*. \[[@B26]\] reported a positive relationship between *HLA-DRB1\*0405* and anti-aminoacyl-tRNA synthetase autoantibodies in Japanese IIM patients. In addition, O'Hanlon *et al.* found that the *HLA-DRB1\*0302* allele is closely linked to myositis-specific anti-Mi-2 autoantibodies in DM \[[@B4]\]. In our study, the numbers of patients with MSA and MAA were too small to have sufficient statistical power for further analysis of the relationship between *HLA* alleles and MSA/MAA autoantibodies. It is also noteworthy that a greater frequency of myositis autoantibodies was found among PM patients from our cohort and the cohort reported by Chinoy and colleagues \[[@B20]\]. However, both cohorts were small in size, and in our study we analyzed only a limited number of autoantibodies.

Previous studies suggest that DM and PM may have different pathogeneses. It has been proposed that DM is likely the result of an autoimmune process induced by a humoral response, whereas PM may be caused by a cell-mediated autoimmune process \[[@B17]\]. Thus, it is plausible that DM and PM might have distinctive genetic susceptibilities. Further investigation is warranted to better understand the pathogeneses of these two diseases.

Possible explanations for the differences between the results from our study and those from other studies include the fact that the studies were conducted in different geographic locations with various environmental exposures, the heterogeneity in genetic backgrounds among the different ethnic groups and populations, the number of *HLA* polymorphic alleles analyzed, the different study methodologies used, referral bias, and the age and sex composition of the different study cohorts. The differences in the clinical and immunogenetic features between adult and childhood DM and PM are well documented \[[@B8],[@B31]\].

Our study has some limitations. Although DM and PM are rare conditions and the number of patients in our cohort is the largest compared with similar studies in Chinese patients, it is still a relatively small cohort. It is likely that there are many genes and genetic polymorphisms that may influence DM and PM susceptibility, and we analyzed only a few of them. The data from our study should be validated by further analysis of multiple genes and alleles and their combined impacts on disease susceptibility. Nevertheless, our data shed some light on the genetic susceptibility of adult DM and PM, and may aid in stratifying disease subtypes according to genetic and ethnic backgrounds.

Conclusions
===========

Our study of adult DM and PM in a Chinese population demonstrated that the putative haplotype *DRB1\*07-DQA1\*01-DQB1\*02* and the *DRB1\*07* and *DQA1\*0104* alleles are associated with an increased risk of DM, while *DRB1\*03* is associated with a reduced risk of DM. *DQB1\*0303* may confer protection against the lung complication, and *DRB1\*04*, *DRB1\*12*, and *DRB1\*07-DQA1\*01-DQB1\*02* are associated with an increased risk of developing the lung complication. Furthermore, *DRB1\*07* is associated with an increased risk of developing dysphagia.
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